What Are Hypnozoites and How Do They Cause Malaria?

Hypnozoites are dormant forms of certain malaria parasites that hide inside liver cells, sometimes for months or even years, before suddenly waking up and triggering a fresh bout of illness. They were first definitively identified in 1980 by Wojciech Krotoski and colleagues, though the concept of a sleeping liver stage had been suspected for decades before that. What makes hypnozoites so medically important is that they explain one of malaria’s most frustrating features: relapse. A person can clear every parasite from their blood, feel completely recovered, and then fall sick again weeks or months later because a handful of these silent stowaways reactivated deep in the liver.

How a Mosquito Bite Leads to a Sleeping Parasite

When an infected mosquito bites you, it injects microscopic parasites called sporozoites into your skin. Those sporozoites travel through the bloodstream to the liver, where they invade individual liver cells. In most malaria species, every sporozoite that successfully enters a liver cell begins multiplying immediately, eventually bursting the cell open and releasing thousands of new parasites into the blood. That blood-stage infection is what causes the classic symptoms of malaria: cycling fevers, chills, and anemia.

With the species that form hypnozoites, though, something different happens. Some of the sporozoites that enter liver cells do not start multiplying. Instead, they shrink down into tiny, single-nucleus forms and essentially go to sleep. These are the hypnozoites. They sit quietly inside the liver cell, not growing, not dividing, and not causing any symptoms. The rest of their siblings proceed with normal development, so the person still gets sick from the initial infection. But even after treatment clears the blood-stage parasites, the hypnozoites remain untouched in the liver, invisible to the immune system and to standard malaria drugs that target blood-stage parasites.

Which Malaria Parasites Form Hypnozoites

Not all malaria species have this trick. Of the five species that routinely infect humans, only two are confirmed hypnozoite formers: Plasmodium vivax and Plasmodium ovale. The most dangerous species, Plasmodium falciparum, does not form hypnozoites, which is one reason its treatment strategy differs. P. vivax is the more widespread and better studied of the two relapsing species and is the dominant malaria parasite outside of sub-Saharan Africa.¹

Even within P. vivax, different strains vary in how readily they produce hypnozoites. Research using liver-cell cultures infected with field isolates from different patients has shown that the proportion of parasites that become dormant rather than developing immediately can range from nearly zero to over 40 percent, depending on the particular parasite strain.² The decision to go dormant appears to be partly built into the parasite’s own biology and partly influenced by the host liver cell it lands in. Studies have found that both the specific parasite isolate and the characteristics of the individual liver cell affect whether a given sporozoite becomes a hypnozoite or begins developing immediately.³ African P. vivax isolates have also been confirmed to produce hypnozoites, though again at varying rates between patients.⁴

What Keeps Them Dormant

One of the biggest open questions about hypnozoites is what molecular switch keeps them asleep and, later, what flips it. Under the microscope, hypnozoites look deceptively simple: small, round, with a single nucleus, measuring roughly 7 to 10 micrometers across. They do grow very slightly over time, but they do not divide or produce the structural changes seen in actively developing liver parasites.⁵

At the genetic level, hypnozoites are not completely shut down, but their activity is dramatically reduced. When researchers captured and sequenced the RNA inside hypnozoites, they found that only a small number of genes were being read at relatively high levels compared with the actively growing stage.⁵ More recent work has pointed to a role for epigenetic regulation, specifically tightly packed DNA structures called heterochromatin, in keeping the parasite dormant. Rather than a single master gene flipping dormancy on and off, the evidence suggests that a set of proteins controlling RNA processing may be the gatekeepers preventing the parasite from progressing through its developmental program.⁶

The parasites also appear to actively manipulate their host liver cell to stay hidden. Liver-stage malaria parasites, including hypnozoites, develop a network of tubes and vesicles extending from the membrane that surrounds them within the liver cell. This network seems to serve a dual purpose: it helps the parasite scavenge nutrients from the host cell, and it may strip away immune-recognition markers from the surrounding membrane, making the infected cell less visible to the body’s defenses.⁷

What Triggers a Relapse

If dormancy is one mystery, reactivation is the other. Hypnozoites can persist in the liver as single-nucleus parasites for extended periods; in primate studies, they have been found still dormant more than 200 days after the initial infection.⁸ At some point, one or more of them “wake up,” begin multiplying inside the liver cell, and eventually release a fresh wave of parasites into the bloodstream. The person then experiences another episode of malaria, clinically identical to the first, without being bitten again.

The leading theory for what triggers this reactivation involves the body’s own inflammatory response. Evidence from epidemiological and clinical observations suggests that a systemic febrile illness, whether from a new malaria infection, a bacterial infection, or another parasitic disease, can provoke dormant hypnozoites to activate. Interestingly, viral infections do not seem to have the same effect, pointing to specific components of the inflammatory response rather than fever alone as the likely trigger.⁹ In areas where malaria is common, a large share of the population may be silently carrying hypnozoites that can be jolted awake by any qualifying systemic illness.¹⁰

This creates a vicious feedback loop in endemic regions. A person harboring dormant hypnozoites gets a new mosquito-borne malaria infection. The resulting fever and inflammation wake up the hypnozoites, amplifying the parasite load and extending the period during which that person can infect new mosquitoes. It is an elegant survival strategy for the parasite, even if it is deeply inconvenient for the host.

Geography Shapes the Relapse Clock

One of the more striking features of P. vivax relapse is that its timing varies predictably by geography. Tropical strains tend to relapse quickly, often within three to six weeks. Strains found in temperate regions, where mosquito seasons are short, tend to have much longer dormancy periods, sometimes eight months or more. A global analysis of relapse patterns found that this geographic variation mapped neatly onto historical ecological classifications of malaria transmission zones, with high relapse frequency predominating in the tropics and prolonged dormancy in temperate areas.¹¹

This makes evolutionary sense. In the tropics, mosquitoes breed year-round, so there is no advantage to waiting; a quick relapse means more chances to be picked up by a mosquito and spread. In temperate zones, mosquitoes vanish during winter. A parasite that relapsed in January would have no way to complete its life cycle. By lying dormant through the cold months and reactivating in spring when mosquitoes return, the parasite ensures its own transmission. Researchers have proposed that this long-latency pattern evolved as early human ancestors moved into colder climates with shorter mosquito breeding seasons, making dormancy a necessary survival adaptation for the parasite.¹²

Why You Cannot Test for Them

Perhaps the most clinically frustrating thing about hypnozoites is that there is currently no way to know whether a person is carrying them. They produce no symptoms, shed no detectable signal into the blood, and sit in numbers too small and scattered to show up on any imaging. Standard malaria blood tests detect parasites circulating in the bloodstream. A person whose blood has been cleared of parasites will test negative even if their liver is harboring dozens of dormant hypnozoites ready to reactivate.¹³

Researchers have been searching for biomarkers, measurable substances in the blood that would indicate a latent liver infection. One promising direction involves studying tiny membrane-enclosed particles that infected liver cells release into the bloodstream. Proteomic work has identified candidate proteins from these particles that differ between hypnozoite-infected and uninfected cells, but no validated diagnostic test has emerged yet.¹⁴ Until such a test exists, clinicians in endemic areas face a difficult choice: treat everyone who has had P. vivax malaria with anti-hypnozoite drugs on the assumption they might be carrying dormant parasites, or accept the risk of relapse.

Treating What You Cannot See

Standard antimalarials like chloroquine and artemisinin-based therapies are effective at killing parasites in the blood but do nothing to hypnozoites in the liver. For decades, the only drug capable of clearing hypnozoites was primaquine, an 8-aminoquinoline that requires a 14-day course to work. That treatment regimen is often called “radical cure” because it aims to eliminate not just the symptoms but the hidden reservoir in the liver.

The problem with primaquine is twofold. First, 14 days is a long course for patients in resource-limited settings, and adherence is often poor. In Brazil, for example, estimates of full adherence to the standard primaquine regimen range from about 62 to 86 percent.¹⁵ Someone who stops taking the drug early may not fully clear their hypnozoites, setting themselves up for a relapse.

Second, and more seriously, primaquine and all 8-aminoquinolines can cause dangerous destruction of red blood cells in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme condition that is itself most common in malaria-endemic regions. An individual patient data meta-analysis found that higher daily primaquine doses were associated with greater drops in hemoglobin, with the risk concentrated in patients who had lower G6PD enzyme activity. The analysis found that for patients with at least 70 percent of normal G6PD activity, standard-dose primaquine carried a risk of serious hemoglobin drops similar to that seen in patients who received no primaquine at all.¹⁶ For patients with lower G6PD activity, the picture is riskier, and screening before prescribing is considered essential.

In 2018, the FDA approved tafenoquine, a newer 8-aminoquinoline with a much longer half-life that allows it to be given as a single dose rather than a 14-day course.¹⁷ This is a significant practical improvement: one pill versus two weeks of pills. However, tafenoquine carries the same G6PD-related hemolysis risk.¹⁸ Its long half-life is a double-edged sword here: if a patient with undiagnosed G6PD deficiency takes it, the drug lingers in the body for weeks, and the resulting red blood cell destruction cannot be quickly reversed by simply stopping the medication. G6PD testing before treatment is mandatory, which adds cost and logistical complexity in exactly the settings where P. vivax is most common.

The Obstacle to Malaria Elimination

From a public health perspective, hypnozoites represent one of the most significant barriers to eliminating vivax malaria globally. Eradication campaigns can spray for mosquitoes, distribute bed nets, and treat every symptomatic case, and yet the parasite persists because an unknowable number of apparently healthy people carry dormant hypnozoites in their livers. Each one of those silent carriers is a potential source of new transmission the next time a hypnozoite wakes up and parasites re-enter the bloodstream.¹⁹

This hidden reservoir is what makes P. vivax control strategies fundamentally different from those aimed at P. falciparum. For P. falciparum, treating all blood-stage infections and preventing new mosquito bites can, in principle, interrupt transmission entirely. For P. vivax, you also need to clear the liver reservoir in every carrier, a task that is currently impossible without a diagnostic test to identify who needs treatment and safe drugs that work for all patients regardless of their G6PD status.¹

Why Research Has Been So Difficult

P. vivax hypnozoites are notoriously hard to study. Unlike P. falciparum, which can be continuously cultured in the laboratory using human red blood cells, P. vivax cannot be maintained in long-term blood-stage culture. And studying liver stages is even harder: you need fresh sporozoites from infected mosquitoes, viable human liver cells, and a culture system that keeps those liver cells healthy long enough for hypnozoites to form and persist. Much of what we know about hypnozoite biology has come from painstaking work with primary human liver cell cultures infected with parasites obtained from patients in endemic areas.

Animal models have also been limited. Common laboratory mice are not susceptible to P. vivax infection. The recent development of humanized mouse models, in which mice are engineered to carry transplanted human liver cells, has opened a new window. These mice can support the full liver-stage development of P. vivax, including hypnozoite formation, making it possible for the first time to study dormancy and test drugs against it in a living animal.²⁰

Drug screening for anti-hypnozoite compounds is also tricky because timing matters. In culture-based assays, drugs applied in the first few days after infection can kill immature hypnozoites that have not yet fully entered dormancy. A truly effective radical cure drug needs to kill mature hypnozoites, those that have been dormant for five or more days, and drug screening platforms have to be designed accordingly to avoid false positives from drugs that work only against the immature forms.²¹

Searching for New Biological Leads

With the limitations of 8-aminoquinolines well established, there is strong interest in finding entirely new classes of drugs that can kill hypnozoites without the G6PD-related toxicity. One avenue involves understanding the metabolic footprint of dormant parasites. Recent work has shown that hypnozoite-infected liver cells produce a distinct set of metabolites, small chemical byproducts of the parasite’s low-level activity, that differ from those produced by uninfected cells or cells harboring actively growing parasites.¹³ Identifying these metabolic pathways could both point toward new drug targets and lay the groundwork for the long-sought diagnostic test for latent infection.

Another line of research focuses on the epigenetic controls described earlier. If dormancy is maintained by specific proteins that control how the parasite’s DNA is read, those proteins become attractive drug targets. Disrupting the machinery that keeps a hypnozoite asleep might force it into active development, where existing blood-stage drugs could then destroy it. Alternatively, permanently locking the parasite in dormancy, preventing reactivation entirely, could be just as useful clinically, though the practical challenges of ensuring a drug reached every scattered hypnozoite in the liver would be enormous. For now, the field is still working out the basic biology of how dormancy is maintained and broken, and translating that into an actual medicine remains years away.

1
PubMed. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination
2
PubMed Central. Plasmodium vivax latent liver infection is characterized by persistent hypnozoites, hypnozoite-derived schizonts, and time-dependent efficacy of primaquine
3
PubMed Central. Liver-stage fate determination in Plasmodium vivax parasites: Characterization of schizont growth and hypnozoite fating from patient isolates
4
PubMed Central. Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs
5
Cell Host & Microbe. Complete Liver-Stage Development and Dormancy of Plasmodium vivax in Human Liver Platform
6
Cell Reports. Heterochromatin-mediated control of hypnozoite dormancy in relapsing malaria parasites
7
Frontiers in Cellular and Infection Microbiology. Characterization of the Tubovesicular Network in Plasmodium vivax Liver Stage Hypnozoites and Schizonts
8
PubMed Central. The hypnozoite and relapse in primate malaria
9
The Lancet Infectious Diseases. The activation of vivax malaria hypnozoites by infectious diseases
10
PubMed Central. Determinants of relapse periodicity in Plasmodium vivax malaria
11
PubMed Central. Geographical variation in Plasmodium vivax relapse
12
PubMed Central. Why Do Some Primate Malarias Relapse?
13
PLOS Pathogens. In vitro cultured malaria hypnozoites leave a footprint of specific metabolites
14
Molecular & Cellular Proteomics. Proteomic Profiling of Extracellular Vesicles from Plasmodium vivax Hypnozoites and Schizonts Identifies Candidate Biomarkers for Latent Liver Infection
15
PubMed Central. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model
16
The Lancet Infectious Diseases. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
17
PubMed Central. Tafenoquine: A Step toward Malaria Elimination
18
PubMed Central. Tafenoquine and G6PD: a primer for clinicians
19
PubMed Central. Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication
20
Frontiers in Cellular and Infection Microbiology. Advancing Key Gaps in the Knowledge of Plasmodium vivax Cryptic Infections Using Humanized Mouse Models and Organs-on-Chips
21
Nature Communications. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum